The Legal Examiner Affiliate Network The Legal Examiner The Legal Examiner The Legal Examiner search feed instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

Amazing! Just days after ruling that Roundup weed killer was a “substantial factor” in causing plaintiff Edwin Hardeman to develop cancer, the same jury awarded him $80 million in damages.

This case is the second to go to trial against Monsanto (now owned by Bayer) for its failure to warn about the deadly dangers of using the glyphosate-based herbicide. Thousands of people are bringing claims similar to Hardeman’s, alleging that Roundup use causes users to develop non-Hodgkins lymphoma and other cancers. Hardeman’s complaint notes that he had used Roundup on his 56-acre property for more than 20 years. He was diagnosed with non-Hodgkins lymphoma in February 2015.

Jennifer Moore, who serves as co-lead counsel in the litigation with Aimee Wagstaff, called the verdict history making. “Today the jury sent a message loud and clear that companies should no longer put products on the market for anyone to buy without being truthful, without testing, and without warning if it causes cancer,” Jennifer said. “They chose not to tell the American public and they chose not to tell the world that their product was dangerous and today the jury held unanimously that that was wrong, it was deceitful and it was malicious.”

Last summer, Monsanto requested the cases be dismissed altogether, a motion which Judge Vince Chhabria denied. One month later, the first case to go to trial resulted in a $289 million verdict for a school groundskeeper who developed terminal non-Hodgkin’s lymphoma.

We at Milestone commend the outstanding legal work that Jennifer, Aimee, and the rest of the plaintiffs’ trial team continue to provide. To echo Jennifer’s comment, victories like this show large corporations like Bayer that they will answer for their negligence in allowing their products to threaten people’s lives without warning.

Comments for this article are closed, but you may still contact the author privately.